NKGen Biotech (NKGN) News Today → The “Next Bitcoin”? 10 CENT Crypto Set to Explode (From True Market Insiders) (Ad) Free NKGN Stock Alerts $1.61 -0.37 (-18.69%) (As of 04/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineNKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summitfinance.yahoo.com - April 25 at 7:03 PMNKGen Biotech Presents Updated NK Cell Therapy Data for Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summitglobenewswire.com - April 25 at 4:05 PMNKGen Biotech Announces Upcoming Publication at the 2024 American Society of Clinical Oncology (ASCO) Annual Meetingglobenewswire.com - April 24 at 4:45 PMReplicate Bioscience Announces Oral Presentations at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meetingfinance.yahoo.com - April 22 at 6:43 PMWhat's Going On With Nano-Cap NKGen Biotech Stock On Monday?finance.yahoo.com - April 22 at 6:43 PMNKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer’s & Parkinson’s Drug Development Summitfinance.yahoo.com - April 18 at 6:39 PMNKGen Biotech Announces Upcoming Presentation on SNK01 NK Cell Therapy in Neurodegenerative Disease at the 12th Annual Alzheimer's & Parkinson's Drug Development Summitglobenewswire.com - April 18 at 4:05 PMNKGN Stock Earnings: NKGen Biotech Reported Results for Q4 2023investorplace.com - April 17 at 1:03 AMNKGen Biotech Secures Additional Financing of $5 Million to Continue Advancing Its Clinical Programsglobenewswire.com - April 11 at 8:05 AMNKGen Biotech Presents Additional Phase 1 Clinical Trial Data in Alzheimer's Disease at the Tau2024 Global Conferenceglobenewswire.com - March 25 at 4:05 PMNKGen Biotech appoints new chairperson amid leadership shuffleinvesting.com - March 22 at 11:04 PMWhy Is NKGen Biotech (NKGN) Stock Up 62% Today?investorplace.com - March 6 at 7:52 AMNKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer’s Disease at the Tau2024 Global Conferencefinance.yahoo.com - March 4 at 10:02 AMNKGen Biotech Announces Upcoming Presentation on SNK01 in Alzheimer's Disease at the Tau2024 Global Conferenceglobenewswire.com - March 4 at 8:00 AMAlana McNulty Exits NKGen Biotech’s Board and Committeesmsn.com - February 9 at 2:40 PMPassage of the Amendment to the Advanced Regenerative Biotech Act a Positive Catalyst for Korean and Japanese Cell Therapy Companiesfinance.yahoo.com - February 7 at 2:02 PMNKGen Biotech Inc (NKGN)investing.com - January 3 at 11:33 PMNKGen Biotech Advances Alzheimer's Treatment with SNK01: First Patient Dosed in Phase 1/2a Trialfinance.yahoo.com - December 29 at 7:38 AMNKGen Biotech, Inc. Announces Dosing of First Patient in its Phase 1/2a Trial with Autologous NK Cell Product, SNK01, for the Treatment of Moderate Alzheimer’s Diseasefinance.yahoo.com - December 28 at 8:50 PMNKGen Biotech Gets Clearance to Begin Alzheimer's Disease Treatment Trials in Canadamarketwatch.com - December 27 at 12:03 PMNKGen Biotech Receives Clearance For SNK01 NK Cell Therapy Clinical Trial From Health Canadamarkets.businessinsider.com - December 27 at 12:03 PMNKGen Biotech Announces Clearance of Clinical Trial Application by Health Canada for SNK01 NK Cell Therapy to Treat Alzheimer’s Diseasefinance.yahoo.com - December 27 at 12:03 PMNKGN NKGen Biotech, Inc.seekingalpha.com - November 30 at 10:05 AMNKGen Biotech GAAP EPS of -$2.48seekingalpha.com - November 15 at 2:27 PMNKGen Biotech, Inc. Reports Third Quarter 2023 Financial Results and Business Highlightsfinance.yahoo.com - November 14 at 7:41 PMNKGen Biotech Inc NKGNmorningstar.com - November 7 at 4:52 PMNKGen Announces Poster Presentation at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023finance.yahoo.com - November 7 at 4:52 PMNKGen Biotech Presents Interim Phase I Trial Data at the XXVI World Congress of Neurology (WCN) Annual Meeting 2023finance.yahoo.com - November 7 at 4:52 PMNKGen Biotech Announces Poster Presentation at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conferencefinance.yahoo.com - November 7 at 4:52 PMNKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer’s Diseasefinance.yahoo.com - November 7 at 4:52 PMNKGEN Biotech Received FDA Approval for Clinical Trials of SKN01 NK Cell Therapy in Alzheimer’s Disease Treatment.finance.yahoo.com - November 7 at 4:52 PMNKGen Biotech Presented Phase I Clinical Trial Data at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conferencefinance.yahoo.com - November 7 at 4:52 PMWhy Is NKGen Biotech (NKGN) Stock Up 18% Today?investorplace.com - October 27 at 9:12 AM Get NKGen Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (Ad)If you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.) Watch my video for all of the details NKGN Media Mentions By Week NKGN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NKGN News Sentiment▼0.330.32▲Average Medical News Sentiment NKGN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NKGN Articles This Week▼51▲NKGN Articles Average Week Get NKGen Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for NKGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SAB Biotherapeutics News OKYO Pharma News Dyadic International News Cidara Therapeutics News Quince Therapeutics News Brainstorm Cell Therapeutics News Cyclo Therapeutics News Protara Therapeutics News IN8bio News Achilles Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:NKGN) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyProtect Your Bank Account Before It’s Too LateWeiss RatingsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThey say it’s ‘unstoppable’ – How I made 43,509% Investing Daily Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NKGen Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
